Conatus Pharmaceuticals (CNAT) Emricasan Phase 2 Met Primary Endpoint in NAFLD

March 26, 2015 7:04 AM EDT Send to a Friend
Conatus Pharmaceuticals (NASDAQ: CNAT) announced top-line results from the company's Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login